Showing 3321-3330 of 8889 results for "".
- New Review Highlights TWEAK/Fn14 Pathway's Potentialhttps://practicaldermatology.com/news/new-review-highlights-tweakfn14-pathways-potential/2484097/A new review published in International Immunopharmacology explores the expanding role of the TWEAK/Fn14 signaling pathway in both skin disease pathogenesis and stem cell regulation, proposing its potential as a dual-purpose
- New Deuruxolitinib Data Show It Meets 'The Need for Speed'https://practicaldermatology.com/news/new-deuruxolitinib-data-show-it-meets-the-need-for-speed/2484089/Deuruxolitinib resulted in significant hair regrowth starting at Week 8, continually improving through Week 24, and the 8-mg and 12-mg BID doses showed significant efficacy vs placebo across subgroups, according to new data presented at the 2025 Fall Clinical Dermatology Conference. Other
- Arcutis Presents New ZORYVE Data in AD at Fall Clinical 2025https://practicaldermatology.com/news/arcutis-presents-new-zoryve-data-in-ad-at-fall-clinical-2025/2484062/Updates and new data sets from the INTEGUMENT trial program, including new quality-of-life and efficacy data for ZORYVE® (roflumilast) cream in pediatric and adult patients with atopic dermatitis (AD), were featured at the 2025 Fall Clinical Dermatology Conference
- Lower Neighborhood SES Linked to Increased HS Severity at Diagnosis: Analysishttps://practicaldermatology.com/news/lower-neighborhood-ses-linked-to-increased-hidradenitis-suppurativa-severity-at-diagnosis/2483997/New research suggests that lower neighborhood socioeconomic status (nSES) was associated with more severe hidradenitis suppurativa (HS) at the time of diagnosis. The recent cross-sectional analysis of 462 patients newly diagno
- Study: Vagus Nerve Stimulation Improves ETR Symptomshttps://practicaldermatology.com/news/study-vagus-nerve-stimulation-improves-etr-symptoms/2483900/Results from a recent study suggest transcutaneous auricular vagus nerve stimulation (taVNS) could be a viable therapeutic option for patients with erythematotelangiectatic rosacea (ETR). Researchers for the randomized, double-
- Study: Nicotinamide Linked with Reduced Skin Cancer Risk Following First Diagnosishttps://practicaldermatology.com/news/va-study-finds-nicotinamide-reduces-skin-cancer-risk-after-first-diagnosis/2483481/A large Veterans Affairs (VA) cohort study has found that nicotinamide supplementation is associated with a reduced risk of subsequent skin cancers, particularly when initiated after a patient’s first diagnosis. Researchers on t
- Galderma to Present Long-Term Nemluvio Data, Global Sensitive Skin Survey at EADV 2025https://practicaldermatology.com/news/galderma-to-present-long-term-nemluvio-data-global-sensitive-skin-survey-at-eadv-2025/2483331/Galderma will present new findings on sensitive skin, as well as long-term data on nemolizumab (Nemluvio®) at the 34th European Academy of Dermatology and Venereology (EADV) Congress, to be held in Paris, September 17–20, 2025, a press statement from the manufactur
- NB-UVB Phototherapy Effective for Psoriasis in Skin of Colorhttps://practicaldermatology.com/news/nb-uvb-phototherapy-effective-for-psoriasis-in-skin-of-color/2483263/A new systematic review and meta-analysis confirms that narrowband ultraviolet B (NB-UVB) phototherapy is effective for psoriasis in patients with skin of color, underscoring its role as a valuable treatment option despite the widespread adoption of biologics and systemic agents.
- Analysis Links NHR With Increased Risk of PsOhttps://practicaldermatology.com/news/analysis-links-nhr-with-increased-risk-of-pso/2483261/The neutrophil-to-high-density lipoprotein cholesterol ratio (NHR) is independently associated with an increased risk of psoriasis, raising the possibility of a novel biomarker for risk stratification, according to a large cross-sectional analysis of US adults published in Frontiers in Immuno
- Bimekizumab Achieves Dual Clearance of Nail and Skin Psoriasishttps://practicaldermatology.com/news/bimekizumab-achieves-dual-clearance-of-nail-and-skin-psoriasis/2483170/In pooled analyses of phase III and IIIb trials, bimekizumab was associated with significantly higher rates of complete clearance of both skin and nail psoriasis compared to adalimumab, ustekinumab, and secukinumab in patients with moderate-to-severe plaque psorias